Advancements in RNA sequencing are paving the way for improved diagnosis of rare diseases. A research team from the Children’s Hospital of Philadelphia (CHOP) has developed a novel RNA sequencing technique that reveals how genetic variants disrupt gene function. This innovative platform, detailed in a recent study published in Science Advances, has successfully identified disease-causing variants and provided molecular diagnoses for previously undiagnosed patients, including five individuals who had exhausted standard testing options.
Limitations of Traditional Sequencing Methods
Exome and genome sequencing are commonly employed to pinpoint genetic variants linked to rare diseases. However, these methods have a diagnostic yield ranging from just 20% to 50%. This means that over half of patients with suspected rare diseases remain without a molecular diagnosis. Many genetic variants affect disease by altering RNA transcription and processing, which cannot be fully understood through DNA sequencing alone. Consequently, there is a growing interest in RNA sequencing as a means to gain deeper insights into how genetic variants influence gene activity and contribute to disease.
The Power of RNA in Diagnostics
RNA serves as a vital tool in diagnosing rare diseases. By examining RNA molecules directly, researchers can obtain a more comprehensive understanding of how genetic variants modify gene products, which is often beyond the scope of DNA analysis.
Overcoming Challenges with Long-Read RNA Sequencing
Traditional RNA sequencing methods typically fragment RNA molecules before sequencing, complicating efforts to reconstruct full-length RNA sequences and connect disease-related variants to abnormal RNA processing events. Long-read RNA sequencing offers a solution by enabling the direct sequencing of complete RNA molecules from end to end. However, challenges such as accuracy, cost, and scalability have hindered its widespread application for rare diseases until now.
Introducing STRIPE: A Targeted Solution
To tackle these obstacles, the CHOP team created STRIPE (Sequencing Targeted RNAs Identifies Pathogenic Events), a targeted long-read RNA sequencing approach. STRIPE facilitates deep sequencing of full-length RNA molecules tailored to specific disease-related gene panels. This method is built on prior innovations at CHOP, particularly TEQUILA-seq, which was designed to make targeted long-read RNA sequencing both cost-effective and scalable.
Cost-Effectiveness of STRIPE
Co-senior author Lan Lin, PhD, noted that TEQUILA-seq aimed to reduce the expense of long-read RNA sequencing. With an RNA-to-data cost of approximately $100 per sample, STRIPE allows for ultra-deep sequencing of disease-related genes on a scale that is practical for clinical use.
Evaluating the Effectiveness of STRIPE
The researchers applied STRIPE to two well-studied groups of rare diseases at CHOP: congenital disorders of glycosylation (CDG) and primary mitochondrial diseases (PMD). These diseases are genetically diverse, with new variants continually being identified, making them ideal for assessing STRIPE’s effectiveness.
Addressing Diagnostic Challenges
Co-senior author Rebecca Ganetzky, MD, emphasized the difficulty in obtaining disease-relevant tissues for RNA analysis. STRIPE allows for high-quality RNA analysis from accessible tissues like skin fibroblasts and blood, ensuring that essential disease signals are captured for interpreting the RNA-level effects of genetic variants.
Real-World Applications and Successes
Researchers tested STRIPE on 88 individuals from the two disease groups, along with healthy controls. The platform successfully re-identified known disease-causing variants and uncovered the complex consequences of these variants at the RNA level. Notably, STRIPE clarified the significance of variants previously deemed uncertain and identified new disease-causing variants in five undiagnosed patients, enabling clinicians to achieve molecular diagnoses that had previously eluded them.
Since its inception, STRIPE has been utilized to analyze over 500 patients across various clinical programs at CHOP, showcasing its scalability and potential in rare disease diagnostics.
Bridging Diagnosis and Treatment
By elucidating how genetic variants disrupt RNA molecules, STRIPE creates a connection between genetic diagnosis, disease mechanisms, and targeted therapies. This research underscores a long-term commitment to interpreting genetic variants through the lens of full-length RNA molecules, thereby laying the groundwork for RNA-based precision medicine in rare diseases.
In conclusion, the development of the STRIPE platform represents a significant advancement in the diagnosis of rare diseases. By enhancing our understanding of RNA and its relationship to genetic variants, STRIPE not only improves diagnostic accuracy but also opens up new avenues for targeted therapeutic interventions. This innovative approach holds promise for transforming the landscape of rare disease diagnosis and treatment, ultimately benefiting countless patients who have long faced diagnostic uncertainties.
- Takeaways:
- STRIPE enables detailed analysis of RNA to better understand rare disease mechanisms.
- The platform identifies new disease-causing variants in previously undiagnosed patients.
- STRIPE represents a cost-effective solution for targeted RNA sequencing in clinical settings.
Read more → www.news-medical.net